222 related articles for article (PubMed ID: 34034619)
1. Anti-tumor effect of trametinib in bladder cancer organoid and the underlying mechanism.
Elbadawy M; Sato Y; Mori T; Goto Y; Hayashi K; Yamanaka M; Azakami D; Uchide T; Fukushima R; Yoshida T; Shibutani M; Kobayashi M; Shinohara Y; Abugomaa A; Kaneda M; Yamawaki H; Usui T; Sasaki K
Cancer Biol Ther; 2021 Jun; 22(5-6):357-371. PubMed ID: 34034619
[TBL] [Abstract][Full Text] [Related]
2. Establishment of a novel experimental model for muscle-invasive bladder cancer using a dog bladder cancer organoid culture.
Elbadawy M; Usui T; Mori T; Tsunedomi R; Hazama S; Nabeta R; Uchide T; Fukushima R; Yoshida T; Shibutani M; Tanaka T; Masuda S; Okada R; Ichikawa R; Omatsu T; Mizutani T; Katayama Y; Noguchi S; Iwai S; Nakagawa T; Shinohara Y; Kaneda M; Yamawaki H; Sasaki K
Cancer Sci; 2019 Sep; 110(9):2806-2821. PubMed ID: 31254429
[TBL] [Abstract][Full Text] [Related]
3. Establishment of 2.5D organoid culture model using 3D bladder cancer organoid culture.
Abugomaa A; Elbadawy M; Yamanaka M; Goto Y; Hayashi K; Mori T; Uchide T; Azakami D; Fukushima R; Yoshida T; Shibutani M; Yamashita R; Kobayashi M; Yamawaki H; Shinohara Y; Kaneda M; Usui T; Sasaki K
Sci Rep; 2020 Jun; 10(1):9393. PubMed ID: 32523078
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of MEK suppresses hepatocellular carcinoma growth through independent MYC and BIM regulation.
Zhou X; Zhu A; Gu X; Xie G
Cell Oncol (Dordr); 2019 Jun; 42(3):369-380. PubMed ID: 30788663
[TBL] [Abstract][Full Text] [Related]
5. Anti-cancer activity of Chaga mushroom (
Abugomaa A; Elbadawy M; Ishihara Y; Yamamoto H; Kaneda M; Yamawaki H; Shinohara Y; Usui T; Sasaki K
Front Pharmacol; 2023; 14():1159516. PubMed ID: 37153767
[TBL] [Abstract][Full Text] [Related]
6. Preclinical activity of EGFR and MEK1/2 inhibitors in the treatment of biliary tract carcinoma.
Cavalloni G; Peraldo-Neia C; Varamo C; Chiorino G; Sassi F; Aglietta M; Leone F
Oncotarget; 2016 Aug; 7(32):52354-52363. PubMed ID: 27429047
[TBL] [Abstract][Full Text] [Related]
7. Trametinib plus 4-Methylumbelliferone Exhibits Antitumor Effects by ERK Blockade and CD44 Downregulation and Affects PD-1 and PD-L1 in Malignant Pleural Mesothelioma.
Cho H; Matsumoto S; Fujita Y; Kuroda A; Menju T; Sonobe M; Kondo N; Torii I; Nakano T; Lara PN; Gandara DR; Date H; Hasegawa S
J Thorac Oncol; 2017 Mar; 12(3):477-490. PubMed ID: 27867002
[TBL] [Abstract][Full Text] [Related]
8. Establishment of an experimental model of normal dog bladder organoid using a three-dimensional culture method.
Elbadawy M; Fujisaka K; Yamamoto H; Tsunedomi R; Nagano H; Ayame H; Ishihara Y; Mori T; Azakami D; Uchide T; Fukushima R; Abugomaa A; Kaneda M; Yamawaki H; Shinohara Y; Omatsu T; Mizutani T; Usui T; Sasaki K
Biomed Pharmacother; 2022 Jul; 151():113105. PubMed ID: 35605292
[TBL] [Abstract][Full Text] [Related]
9. Low‑dose trametinib and Bcl‑xL antagonist have a specific antitumor effect in KRAS‑mutated colorectal cancer cells.
Koyama M; Kitazawa M; Nakamura S; Matsumura T; Miyazaki S; Miyagawa Y; Muranaka F; Tokumaru S; Okumura M; Yamamoto Y; Ehara T; Hondo N; Takahata S; Takeoka M; Miyagawa SI; Soejima Y
Int J Oncol; 2020 Nov; 57(5):1179-1191. PubMed ID: 32901840
[TBL] [Abstract][Full Text] [Related]
10. The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanoma.
Simbulan-Rosenthal CM; Dakshanamurthy S; Gaur A; Chen YS; Fang HB; Abdussamad M; Zhou H; Zapas J; Calvert V; Petricoin EF; Atkins MB; Byers SW; Rosenthal DS
Oncotarget; 2017 Feb; 8(8):12576-12595. PubMed ID: 28157711
[TBL] [Abstract][Full Text] [Related]
11. Identifying the ErbB/MAPK Signaling Cascade as a Therapeutic Target in Canine Bladder Cancer.
Cronise KE; Hernandez BG; Gustafson DL; Duval DL
Mol Pharmacol; 2019 Jul; 96(1):36-46. PubMed ID: 31048548
[TBL] [Abstract][Full Text] [Related]
12. The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4.
Liu L; Mayes PA; Eastman S; Shi H; Yadavilli S; Zhang T; Yang J; Seestaller-Wehr L; Zhang SY; Hopson C; Tsvetkov L; Jing J; Zhang S; Smothers J; Hoos A
Clin Cancer Res; 2015 Apr; 21(7):1639-51. PubMed ID: 25589619
[TBL] [Abstract][Full Text] [Related]
13. Trametinib modulates cancer multidrug resistance by targeting ABCB1 transporter.
Qiu JG; Zhang YJ; Li Y; Zhao JM; Zhang WJ; Jiang QW; Mei XL; Xue YQ; Qin WM; Yang Y; Zheng DW; Chen Y; Wei MN; Shi Z
Oncotarget; 2015 Jun; 6(17):15494-509. PubMed ID: 25915534
[TBL] [Abstract][Full Text] [Related]
14. Biased signaling downstream of epidermal growth factor receptor regulates proliferative versus apoptotic response to ligand.
Ali R; Brown W; Purdy SC; Davisson VJ; Wendt MK
Cell Death Dis; 2018 Sep; 9(10):976. PubMed ID: 30250119
[TBL] [Abstract][Full Text] [Related]
15. ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.
Yun MR; Choi HM; Kang HN; Lee Y; Joo HS; Kim DH; Kim HR; Hong MH; Yoon SO; Cho BC
Oncogene; 2018 Jan; 37(3):377-388. PubMed ID: 28945228
[TBL] [Abstract][Full Text] [Related]
16. A combinatorial strategy for overcoming primary and acquired resistance of MEK inhibition in colorectal cancer.
Chen J; Dai J; Kang Z; Yang T; Zhao Q; Zheng J; Zhang X; Zhang J; Xu J; Sun G; Yang L; Yang T
Exp Cell Res; 2020 Aug; 393(1):112060. PubMed ID: 32407729
[TBL] [Abstract][Full Text] [Related]
17. MEK inhibition overcomes everolimus resistance in gastric cancer.
Liu H; Yao Y; Zhang J; Li J
Cancer Chemother Pharmacol; 2020 Jun; 85(6):1079-1087. PubMed ID: 32444897
[TBL] [Abstract][Full Text] [Related]
18. Relationships between signaling pathway usage and sensitivity to a pathway inhibitor: examination of trametinib responses in cultured breast cancer lines.
Leung EY; Kim JE; Askarian-Amiri M; Rewcastle GW; Finlay GJ; Baguley BC
PLoS One; 2014; 9(8):e105792. PubMed ID: 25170609
[TBL] [Abstract][Full Text] [Related]
19. Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer.
Vujic I; Sanlorenzo M; Posch C; Esteve-Puig R; Yen AJ; Kwong A; Tsumura A; Murphy R; Rappersberger K; Ortiz-Urda S
Oncotarget; 2015 Jan; 6(2):969-78. PubMed ID: 25504439
[TBL] [Abstract][Full Text] [Related]
20. Physapubescin B enhances the sensitivity of gastric cancer cells to trametinib by inhibiting the STAT3 signaling pathway.
Dai C; Shen L; Jin W; Lv B; Liu P; Wang X; Yin Y; Fu Y; Liang L; Ma Z; Zhang X; Wang Y; Xu D; Chen Z
Toxicol Appl Pharmacol; 2020 Dec; 408():115273. PubMed ID: 33035574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
